Our long term goal is to develop an integrated model which will define the salient differences between energy metabolism regulation in slow and fast heart-rate hearts. An understanding of these differences will allow a clearer understanding of the functions in situ of regulatory factors such as the mitochondrial ATPase inhibitor protein (IF1) in human and in other slow heart-rate hearts. The proposed research focuses on both normal regulatory and pathophysiological functions of IF1 in situ in normally functioning hearts and in ischemic cardiac muscle, respectively. Our research plan takes advantage of a species comparative approach to the elucidation of the roles played by IF1, comparing its function or lack thereof in the hearts of both slow and fast heart-rate species. While IF1 effectively slows ATP hydrolysis by the undriven mitochondrial ATP synthase during ischemia in slow heart-rate hearts, it has very little inhibitory action in fast heart-rate hearts. The planned work will address the mechanisms underlying this difference in the regulatory behavior of If1 in slow and fast heart-rate hearts. It will also address the different regulatory characteristics of two other functionally related systems, the mitochondrial phosphate carrier and phosphofructokinase (PFK) in slow and fast heart-rate hearts. pH-dependent, Pi-carrier-mediated Pi/H+ symport is primarily responsible for the drop in mitochondrial matrix pH during ischemia required for the inhibition of the mitochondrial ATPase by IF1, but only in slow heart-rate hearts. PFK stimulation mediates the large increase in glycolytic flux occurring at the onset of ischemia, an increase which is approximately five time larger in fast than in slow heart-rate hearts.
The first aim of the proposed work is to determine the contribution to the net rate of ATP synthesis made by the back reaction rate of the ATP synthase in intact slow versus fast heart-rate heart mitochondria; IF1 binding regulates primarily only the back reaction rate.
Our second aim i s to characterize factors responsible for the lack of IF1 binding observed in fast heart-rate heart mitochondria.
Our third aim i s to quantitate the amounts of inhibitor present in aging and failing human heart mitochondria to see if there may be an inhibitor deficit making them intrinsically more susceptible to ischemia-mediated damage.
Our fourth aim i s to further characterize regulatory differences between the Pi carrier in intact slow versus fast heart-rate heart mitochondria. Our fifth and last aim is to further characterize regulatory differences between the phosphofructokinase present in slow versus fast heart-rate hearts.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Physical Biochemistry Study Section (PB)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Cincinnati
Schools of Medicine
United States
Zip Code
Rouslin, W; Broge, C W (1996) Isoform-independent heart rate-related variation in cardiac myofibrillar Ca(2+)-activated Mg(2+)-ATPase activity. Am J Physiol 270:C1271-6
Rouslin, W; Broge, C W (1996) Novel difference in IF1 reactivity to Zn2+ in rabbit versus rat cardiomyocytes, mitochondria, and submitochondrial particles. Biochem Biophys Res Commun 227:8-14
Rouslin, W; Broge, C W (1996) IF1 function in situ in uncoupler-challenged ischemic rabbit, rat, and pigeon hearts. J Biol Chem 271:23638-41
Rouslin, W; Frank, G D; Broge, C W (1995) Content and binding characteristics of the mitochondrial ATPase inhibitor, IF1, in the tissues of several slow and fast heart-rate homeothermic species and in two poikilotherms. J Bioenerg Biomembr 27:117-25
Rouslin, W; Broge, C W; Guerrieri, F et al. (1995) ATPase activity, IF1 content, and proton conductivity of ESMP from control and ischemic slow and fast heart-rate hearts. J Bioenerg Biomembr 27:459-66
Rouslin, W; Broge, C W (1994) Analysis of factors affecting functional assays for estimating IF1, the mitochondrial ATPase inhibitor. Anal Biochem 222:68-75
Rouslin, W; Broge, C W (1993) Mechanisms of ATP conservation during ischemia in slow and fast heart rate hearts. Am J Physiol 264:C209-16
Rouslin, W; Broge, C W (1993) Factors affecting the species-homologous and species-heterologous binding of mitochondrial ATPase inhibitor, IF1, to the mitochondrial ATPase of slow and fast heart-rate hearts. Arch Biochem Biophys 303:443-50
Rouslin, W; Broge, C W; Chernyak, B V (1993) Effects of Zn2+ on the activity and binding of the mitochondrial ATPase inhibitor protein, IF1. J Bioenerg Biomembr 25:297-306
Rouslin, W; Broge, C W; Chernyak, B V (1992) Zn2+ allows differentiation between two kinds of IF1-ATPase interaction in intact mitochondria. Ann N Y Acad Sci 671:507-8

Showing the most recent 10 out of 25 publications